219.00 USD
▼+0.04-0.60%
盘后 208.05 +1.23%
2026-07-31
市值
$29.30B
市盈率
38.97
EPS
5.62
股息率
—
52 周区间
197.81 – 495.55
成交量
3.11M
Beta
0.30
目标价
386.29
52W 低 197.8152W 高 495.55
价格走势
公司简介
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo...